Home >> Tag Archives: Companion diagnostics —

Tag Archives: Companion diagnostics —

Rebooting IHC for companion diagnostics

January 2016—Immunotherapy has taken cancer treatment by storm. And given the number of proteins that are targets for immunotherapy and other targeted therapies, immunohistochemistry should theoretically be the ideal method for classifying patients as responders versus non-responders. But there are several reasons why IHC hasn’t reached this status within personalized medicine, says Clive R. Taylor, MD, DPhil, professor of pathology in the Keck School of Medicine of the University of Southern California.

Read More »

Pharma strives to aid companion diagnostics

May 2015—M. Elizabeth H. Hammond, MD, is no mind reader. But approach her at a conference or meeting, and she has a pretty good idea what you’re going to ask her. “I was the chair for the 2007 and 2013 ASCO-CAP HER2 guideline, and since that time, the most common question I get from individuals is, ‘How do you know the guideline is making any difference?’” says Dr. Hammond, who is a professor of pathology and adjunct professor of internal medicine at the University of Utah School of Medicine and a consulting pathologist, Intermountain Healthcare.

Read More »